Bong-Chul Chu
Overview
Explore the profile of Bong-Chul Chu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
616
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maiese E, Evans K, Chu B, Irwin D
Am Health Drug Benefits
. 2018 Apr;
11(1):39-46.
PMID: 29692879
Background: In recent years, the development of new therapies for multiple myeloma has improved the survival of patients, but newer treatments may also affect healthcare costs. To date, no real-world...
2.
Levin P, Fan T, Song X, Nero D, Davis B, Chu B
Endocr Pract
. 2017 Aug;
23(11):1316-1324.
PMID: 28816532
Objective: Not all patients with type 2 diabetes achieve recommended glycated hemoglobin A (A1C) levels after adequate titration of basal insulin (BI). Current intensification approaches include addition of rapid-acting insulin...
3.
Gilligan A, Waycaster C, Bizier R, Chu B, Carter M, Fife C
Adv Wound Care (New Rochelle)
. 2017 Apr;
6(4):125-134.
PMID: 28451469
Compare enzymatic debridement using clostridial collagenase ointment (CCO) with autolytic debridement using medicinal honey in the hospital outpatient setting for treating pressure ulcers (PUs). Retrospective deidentified electronic health records from...
4.
Johnston S, Nguyen H, Cappell K, Nelson J, Chu B, Kalsekar I
J Med Econ
. 2015 Apr;
18(9):666-77.
PMID: 25867133
Objective: To compare healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus (T2DM) in the United States newly initiating exenatide once weekly (QW) or liraglutide. Methods:...
5.
Johnston S, Nguyen H, Felber E, Cappell K, Nelson J, Chu B, et al.
Adv Ther
. 2014 Nov;
31(11):1119-33.
PMID: 25408484
Introduction: Greater adherence to medications has been broadly demonstrated to be associated with improved clinical outcomes. However, there is limited real-world evidence on adherence to glucagon-like peptide-1 receptor agonist (GLP-1RA)...
6.
Johnston S, Juday T, Farr A, Chu B, Hebden T
Am J Manag Care
. 2014 Sep;
20(6):448-55.
PMID: 25180433
Objectives: To compare antiretroviral therapy (ART) adherence and persistence and total healthcare expenditures in Medicaid-insured patients with human immunodeficiency virus (HIV) initiating preferred or nonpreferred first-line ART based on March...
7.
Margolis J, Chu B, Wang Z, Copher R, Cavazos J
JAMA Neurol
. 2014 Jun;
71(8):985-93.
PMID: 24911669
Importance: To our knowledge, the current study is the first to describe antiepileptic drug (AED) combination therapy patterns according to their mechanism of action (MOA) in a real-world setting and...
8.
Johnston S, Udall M, Cappelleri J, Johnson B, Shrady G, Chu B, et al.
Pain Med
. 2014 Jan;
15(8):1282-93.
PMID: 24401017
Objective: To quantify the prevalence of potential drug-drug/drug-condition interactions (DDI/DCI) among fibromyalgia patients initiating pregabalin or duloxetine, and to determine the impact of potential DDI/DCI on health care expenditures. Design:...
9.
Johnston S, Udall M, Cappelleri J, Johnson B, Shrady G, Chu B, et al.
Am J Health Syst Pharm
. 2013 Dec;
70(24):2207-17.
PMID: 24296843
Purpose: The frequency and financial impact of potential drug-drug interactions (DDIs) and drug-condition interactions (DCIs) in patients with painful diabetic peripheral neuropathy (DPN) treated with either pregabalin or duloxetine were...
10.
Johnston S, Juday T, Esker S, Espindle D, Chu B, Hebden T, et al.
Value Health
. 2013 Mar;
16(2):418-25.
PMID: 23538194
Objectives: This is the first study to compare the incidence and health care costs of medically attended adverse effects in atazanavir- and darunavir-based antiretroviral therapy (ART) among U.S. Medicaid patients...